跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2007-002174-58-DE
EUCTR2007-002174-58-DE进行中（未招募）不适用

A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome

sanofi-aventis recherche & développement0 个研究点目标入组 36 人开始时间: 2008年5月6日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
36
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Main inclusion criteria:
  • •-OSAHS with an AHI (number/hour) =15 and up to 35 including =60% obstructive or mixed AH.
  • •-Daytime sleepiness or at least 2 of the following: choking/gasping during sleep, recurrent awakenings from sleep, daytime fatigue, unrefreshing sleep, impaired concentration along with irritability or mood swings
  • •Other inclusion criterias:
  • •Related to Subjects:
  • •Out-patients =18 years of age or the legal age of consent in the area where the study is being done male and female patients but less then 75 years.
  • •Related to sleep disorders:
  • •Each subject must have the history of OSAHS for at least one month preceding the study visit.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •Medical condition that may interfere with the study conduct and/or assessment:
  • •-Patients treated by CPAP, oral appliance during 4-week period prior to randomization.
  • •- Chronic respiratory disease (COPD, pulmonary fibrosis or asthma) or FEV/FVC <= 55% by history or PaCO2 <34 mmHg (5 KPa) or PaCO2 >45 mmHg (6 KPa) or PaO2 <67 mm Hg (9 KPa)
  • •- Patient treated with concomitant medication that are known to be strong or moderate CYP3A4 inhibitors. A list is proposed in Appendix C
  • •-Body mass index (BMI) of =20 kg/M2 or =35 kg/M2
  • •-Surgical procedure to correct apnea within the last 3 months.
  • •Related to subjects:
  • •-Women of childbearing potential without effective contraceptive measures, lactating or who are pregnant.
  • •-Inability to meet some specific protocol requirements (eg, need for spending 2 nights in Sleep Laboratory).
  • •-Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  • •-Night shift workers and individuals who napped 3 or more times per week over the preceding month.
  • •-Consumption of xanthine-containing beverages (eg, tea, coffee, or cola) comprising usually more than 5 cups or glasses per day.
  • •-Participation in another trial having received study medication within two months before the screening visit.
  • •-Subjects unwilling or unable to provide written, signed and dated informed consent.
  • •-Subjects who are unable to participate for the entire duration of the study, or in the opinion of the investigator, are likely to be non-compliant with the obligations inherent in the trial participation.
  • •- Patient under legal guardianship
  • •Related to concomitant illnesses:
  • •-Subjects presenting with acute or chronic pain resulting in sleep disturbance.
  • •-Subjects with current active psychiatric disturbances according to DSM IV criteria including but not limited to psychosis, schizophrenia, bipolar disorder, obsessive compulsive disorder, major depression, anxiety disorders, panic disorders, eating disorder, alcohol or substance abuse or dependence -except nicotine-, or a history of lifetime psychosis.
  • •-Subjects with mental retardation or dementia of Alzheimer’s or vascular type.
  • •-Subjects with a history of epilepsy or seizures (not including benign neonatal and childhood convulsions).
  • •-Evidence of any Laboratory abnormality, clinically significant severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety.
  • •This includes the following criteria:
  • •- Creatinine clearance level <=50 mL/min
  • •- Abnormal liver function tests (ALT or AST > 2 times the upper limit of the normal range)
  • •- Hypertension poorly controlled by well-managed treatment, unstable, refractory or severe hypertension (supine or sitting systolic >= 180 / diastolic >= 110 mmHg)
  • •- Past history of stroke within the previous 6 months
  • •- Past history of myocardial infarction within the previous 6 months

研究者

相似试验

进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome
EUCTR2007-002172-34-FRsanofi-aventis recherche & développement36
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome.--------------------------------------------------------------------------------------------Estudio doble ciego, aleatorizado, controlado con placebo para evaluar la seguridad y la actividad de cuatro dosis únicas escalonadas de AVE0657 en pacientes con insuficiencia cardiaca congestiva que presentan el síndrome de la respiración de Cheyne-Stokes.Congestive heart failure patients presenting as Cheyne-Stokes Breathing Syndrome.---------------------------------------------------------------------------------------------------------pacientes con insuficiencia cardiaca congestiva que presentan el síndrome de la respiración de Cheyne-Stokes.MedDRA version: 9.1Level: LLTClassification code 10008501Term: Cheyne-Stokes respiration
EUCTR2007-002172-34-ESsanofi-aventis recherche & développement36
进行中（未招募）
不适用
A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome.-----------------------------------------------------------------------------------------------------Estudio doble ciego, aleatorizado, controlado con placebo para evaluar la seguridad y actividad de cuatro dosis únicas escalonadas de AVE0657 en pacientes que sufren el síndrome de apnea-hipoapnea obstructiva del sueño.
EUCTR2007-002174-58-ESsanofi-aventis recherche & développement36
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome
EUCTR2007-002174-58-FRsanofi-aventis recherche & développement36
进行中（未招募）
不适用
A double-blind, randomized, placebo-controlled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)Patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)
EUCTR2013-002924-17-SEAlbireo AB48